R&G Pharma released its first-quarter performance, with a net profit attributable to the parent company of 26.0737 million yuan, an increase of 13.12%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, R&G Pharma released its first-quarter report for 2025, with operating revenue of 173 million yuan, a year-on-year decrease of 2.53%. The net profit attributable to shareholders of the listed company was 26.0737 million yuan, a year-on-year increase of 13.12%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.415 million yuan, a year-on-year increase of 23.26%. The basic earnings per share were 0.27 yuan
According to the Zhitong Finance APP, R&G Pharma (301333.SZ) released its first-quarter report for 2025, with operating revenue of 173 million yuan, a year-on-year decrease of 2.53%. The net profit attributable to shareholders of the listed company was 26.0737 million yuan, a year-on-year increase of 13.12%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.415 million yuan, a year-on-year increase of 23.26%. The basic earnings per share were 0.27 yuan